Background: The identification and validation of soluble markers provide significant opportunities for managing patients with rheumatic diseases, and calprotectin may be an alternative laboratory biomarker of inflammatory rheumatoid arthritis (RA) and psoriatic arthritis (PsA) even though its levels may vary considerably. The aim of this study was to propose a calprotectin cut-off value that would be useful for distinguishing patients with inflammatory arthritis or noninflammatory arthritis (NIA) in clinical practice.Methods: A commercial enzyme-linked immunosorbent assay was used to measure serum calprotectin levels in patients with RA, ankylosing spondylitis (AS), PsA and controls with NIA. All of the patients had been treated with biological disease-modifying anti-rheumatic drugs (DMARDs) for about 12 months after previous failure on conventional DMARDs. Results: Receiver operating characteristic (ROC) analysis showed that serum calprotectin levels significantly differentiated the samples of the patients with inflammatory rheumatic disease from those of the controls. A serum calprotectin level of > 0.9 μg/mL (the optimal predictive cut-off value in the ROC analysis) had a sensitivity of 95.3%, a specificity of 82.2%, a positive likelihood ratio (LR) of 5.35 and a negative LR of 0.057. Conclusions: Our findings suggest that serum calprotectin levels are useful in clinical practice to distinguish patients with inflammatory arthritis and NIA. Further studies of a larger population are suggested.
Keywords: Calprotectin, inflammatory arthritis, non inflammatory arthritis, disease activity, biomarkers, psoriatic arthritis, rheumatoid arthritis, spondyloarthritis.
Editorial (Thematic Issue: Optimizing Treatment in Rheumatoid Arthritis)
Current Pharmaceutical Design Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Is the Treatment with Biological or Non-biological DMARDS a Modifier of Periodontal Condition in Patients with Rheumatoid Arthritis?
Current Rheumatology Reviews Onset of Hypertension in Leflunamide Treated Low Socioeconomic Rheumatoid Arthritis Patients: An Unseen Iceberg
Current Rheumatology Reviews Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Non-Pharmacologic Treatment Options in Rheumatologic Disease
Current Rheumatology Reviews Selective Matrix Metalloproteinase Inhibitors for Cancer
Current Medicinal Chemistry Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Protein & Peptide Letters The Use of n-3 Polyunsaturated Fatty Acids as Therapeutic Agents for Inflammatory Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Bacterial Toxins: A Hope Towards Angiogenic Ailments
Current Drug Metabolism Wrist Biomechanics: In the Normal Wrist, Following Injury and After Surgical Treatment
Current Rheumatology Reviews The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE
Current Topics in Medicinal Chemistry The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Rheumatoid Arthritis in Southern Europe: Epidemiological, Clinical, Radiological and Genetic Considerations
Current Rheumatology Reviews Vaccination and Rheumatic Diseases: Is There Still a Dilemma?
Current Rheumatology Reviews Recent Patents on Immunoregulatory DNA Vaccines for Autoimmune Diseases and Allograft Rejection
Recent Patents on DNA & Gene Sequences (DIscontinued) Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews Extracellular Tropomyosin: A Novel Common Pathway Target for Anti- Angiogenic Therapy
Current Cancer Drug Targets